Xanthohumol and Viral Infections (XL)

Not Applicable

Recruiting

• Conditions: Infection Viral
• Interventions: Dietary Supplement: Xanthohumol; Dietary Supplement: Placebo

• Registration Number: NCT06286657
• Lead Sponsor: University of Vienna

Brief Summary

The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.

Detailed Description

In this placebo-controlled study, blood is taken on the first day of the study, followed by a 90-day intervention with xanthohumol or a placebo, which is taken twice daily. Blood samples will be taken on day 0, day 45 and day 90. Should the study participants develop a respiratory infection during the study, they will be asked to perform a self-test.

Study Timeline

• Study Start: 2023-08-01
• Study First Submitted: 2024-01-17
• Study First Submitted QC: 2024-02-21
• Study First Posted: 2024-02-29
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-10
• Last Update Posted: 2025-04-15
• Primary Completion: 2025-10-31
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• healthy
• BMI >18 kg/m² or < 28kg/m²

Exclusion Criteria

• food intolerances
• food allergies
• chronic inflammatory diseases
• metabolic diseases
• viral or bacterial infections within the last 3 weeks of inclusion
• intake of immunosuppressive medication
• severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
• influenza infection in the "current" flu season

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention	Xanthohumol	Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
Placebo	Placebo	Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Primary Outcome Measures

Name	Time	Method
Changes in severity and duration of viral infections	90 days	Changes in score of Wisconsin Upper Respiratory Symptom Survey

Secondary Outcome Measures

Name	Time	Method
Changes in cognitive skills	90 days	Assessment of cognitive processes using stroop test
Changes in blood lipid levels	90 days	Changes in triglyceride levels (mg/dl) and cholesterol levels (mg/dl)

Trial Locations

Locations (1)

University of Vienna; 🇦🇹 Vienna, Austria